Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3183 - Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, Phase 2 study


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Akitaka Makiyama


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


A. Makiyama1, E. Oki2, Y. Miyamoto3, M. Kotaka4, H. Kawanaka5, K. Miwa6, A. Kabashima7, T. Noguchi8, K. Yuge9, T. Kashiwada10, M. Shimokawa11, H. Saeki12, Y. Akagi13, H. Baba14, M. Mori15

Author affiliations

  • 1 Hematology/oncology, Japan Community Healthcare Organization Kyushu Hospital, 806-8501 - Kitakyushu/JP
  • 2 Department Of Surgery And Science, Graduate School of Medical Sciences, Kyushu University, 812-8582 - Fukuoka/JP
  • 3 Department Of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto/JP
  • 4 Surgery, Sano Hospital-Gastrointestinal Cancer Centre, 655-0031 - Kobe/JP
  • 5 Clinical Research Institute And Department Of Surgery, National Hospital Organization Beppu Medical Center, Beppu/JP
  • 6 Mutidisciplinary Treatment Cancer Center, Kurume University Hospital, 830-0011 - Kurume/JP
  • 7 Department Of Surgery, Oita Medical Center, Oita/JP
  • 8 Department Of Surgery, Imakiire general hospital, Kagoshima/JP
  • 9 Department Of Surgery, Social Insurance Tagawa Hospital, Tagawa/JP
  • 10 Medical Oncology, Saga Univ Facilty of Medicine-Nabeshima, 849-8501 - Saga/JP
  • 11 Department Of Biostatistics, Yamaguchi University Graduate School of Medicine, 755-0046 - Ube/JP
  • 12 General Surgical Science, Gunma University, Maebashi/JP
  • 13 Surgery, Kurume University, Kurume/JP
  • 14 Gastroenterological Surgery, Graduate school of Life Sciences Kumamoto University, Kumamoto/JP
  • 15 Surgery And Science, Kyushu University, Fukuoka/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3183


Elderly patients often cannot tolerate the usual combination of two cytotoxic agents. Recently, bevacizumab plus trifluridine/tipiracil (FTD/TPI) was shown to be a good candidate regimen for vulnerable patients. We aimed to assess the efficacy and safety of bevacizumab plus FTD/TPI in elderly patients with metastatic colorectal cancer.


Patients aged 70 years or older, with previously untreated unresectable, metastatic colorectal cancer, who were not deemed to be candidates for oxaliplatin-based or irinotecan-based chemotherapy regimens, were included in this trial. The treatment consisted of FTD/TPI (35 mg/m2, twice daily on Days 1–5 and Days 8–12) with bevacizumab (5mg/kg intravenously on Day 1 and 15), administrated every 4 weeks until disease progression. The primary endpoint was progression-free survival (PFS). Based on a previous report, we estimated the expected PFS as 9 months and the lower limit of interest as 5 months. As this research was designed to have a statistical power of 80% and one-sided type I error of 0.10, we calculated that 32 patients were required and planned enrolling 35 patients. The secondary endpoints were response rate (ORR), overall survival (OS), and adverse events (AEs).


Between 2017 January and 2018 March, 39 patients (17 male; 22 female), with a median age of 77.5 years (range: 70–88), ECOG performance status 0 (79.5%) or 1 (20.5%), and RAS WT/MT/Unknown 23.1/41.0/35.9% were enrolled. The median PFS was 8.0 months (80% CI 6.7–11.2), and the median OS was not reached. The best response was 40.5% (15/37; 95% CI: 24.8–57.9), and the disease control rate was 86.5% (32/37; 95% CI: 71.2–95.5). The most frequently occurring grade 3 or 4 AEs were neutropenia (71.8%), leucopenia (48.7%), hypertension (20.5%), anemia (17.9%), anorexia (12.8%), febrile neutropenia (10.3%), and fatigue (10.3%). No treatment-related deaths occurred.


In this Phase 2 KSCC 1602 trial of bevacizumab plus FTD/TPI, the primary endpoint of PFS was achieved. This combination therapy showed favorable survival outcomes with an acceptable safety profile for elderly patients with previously untreated metastatic colorectal cancer.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Kyushu Study group of Clinical Cancer.


Taho Pharmaceutical.


A. Makiyama: Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lily Pharmaceutical; Speaker Bureau / Expert testimony: Chugai Pharmaceutical; Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Takeda Pharmaceutical. M. Kotaka: Honoraria (self): Yakult Honsya; Honoraria (self): Chugai pharmaceutical. H. Baba: Research grant / Funding (institution): Taiho pharmaceutical; Research grant / Funding (institution): Chugai pharmaceutical. M. Mori: Research grant / Funding (institution): Taiho Pharmaceutical Co, Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.